3D bioprinting & tumor models (research)
3D bioprinting builds spatially organized tissue constructs by depositing bioinks (cells + biomaterials) layer by layer. In oncology research it supports more physiological models than flat plastic — but it is not a front-line clinical therapy in the same sense as drugs or radiation.
Why it matters for cancer R&D
- Tumor microenvironment: gradients of oxygen, nutrients, and stromal compartments are hard to mimic in 2D
- Drug screening: test combinations on patient-derived or engineered constructs
- Personalized research models (still largely preclinical; regulatory path varies by jurisdiction)
How this differs from organoids
Organoids are often grown from stem-like cells in Matrigel or similar without a printer. Bioprinting adds designed geometry and multi-material deposition. In practice, teams may combine ideas from both fields.
Ethics and quality
- Consent and provenance for human cells
- Reproducibility: bioink batches, print parameters, and culture conditions must be documented
- Avoid hype: printed tissues for transplant in oncology are experimental and distinct from in vitro screening models
See also
- Tumor microenvironment
- Structural biology (3D structure thinking)
- Tools · Examples